Back to Search Start Over

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.

Authors :
Pan S
Wu X
Jiang J
Gao W
Wan Y
Cheng D
Han D
Liu J
Englund NP
Wang Y
Peukert S
Miller-Moslin K
Yuan J
Guo R
Matsumoto M
Vattay A
Jiang Y
Tsao J
Sun F
Pferdekamper AC
Dodd S
Tuntland T
Maniara W
Kelleher JF 3rd
Yao YM
Warmuth M
Williams J
Dorsch M
Source :
ACS medicinal chemistry letters [ACS Med Chem Lett] 2010 Mar 16; Vol. 1 (3), pp. 130-4. Date of Electronic Publication: 2010 Mar 16 (Print Publication: 2010).
Publication Year :
2010

Abstract

The blockade of aberrant hedgehog (Hh) signaling has shown promise for therapeutic intervention in cancer. A cell-based phenotypic high-throughput screen was performed, and the lead structure (1) was identified as an inhibitor of the Hh pathway via antagonism of the Smoothened receptor (Smo). Structure-activity relationship studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide (5m, NVP-LDE225), which is currently in clinical development.

Details

Language :
English
ISSN :
1948-5875
Volume :
1
Issue :
3
Database :
MEDLINE
Journal :
ACS medicinal chemistry letters
Publication Type :
Academic Journal
Accession number :
24900187
Full Text :
https://doi.org/10.1021/ml1000307